Basilea Pharmaceutica - New supportive data from ERADICATE
Basilea Pharmaceutica has presented detailed data from the Phase III ERADICATE study of Zevtera (ceftobiprole) in the treatment of Staphylococcus aureus bacteraemia (SAB). In this, Zevtera demonstrated an overall success rate of 77.9% (77.8% for daptomycin), a microbiological eradication rate of 82.0% (77.3% for daptomycin), an all-cause mortality rate of 9.0% (9.1% for daptomycin) and a new SAB complications rate of 5.8% (5.6% for daptomycin) at 70 days post-randomisation in the modified intent-to-treat population. Additionally, the median time to bloodstream clearance for methicillin susceptible Staphylococcus aureus (MSSA) was three days with Zevtera (four days with daptomycin), and five days for MRSA for Zevtera and daptomycin. These secondary outcomes add to the previous reporting that ERADICATE met the primary endpoint of non-inferiority versus the comparator arm. We see these new data as supportive of Zevtera’s utility in treating serious bacterial infections and as an important result for the company. Our valuation of Basilea Pharmaceutica is unchanged at CHF903.5m or CHF76.3/share.Basilea Pharmaceutica is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of bacterial infections, fungal infections, oncology and skin diseases. Co. focuses on antibiotics and antifungals as well as oncology and dermatology drugs. Co.'s portfolio spans from innovative early-stage through clinical late-stage drug candidates to a marketed product. In the context of its international commercialization organization, Co. has subsidiaries in Denmark, France, Germany, Italy, Spain and the United Kingdom.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.